Pharmacoeconomics

Papers
(The H4-Index of Pharmacoeconomics is 24. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-07-01 to 2024-07-01.)
ArticleCitations
The Economic Burden of Adults with Major Depressive Disorder in the United States (2010 and 2018)366
A Systematic Review of Medical Costs Associated with Heart Failure in the USA (2014–2020)212
Perspective and Costing in Cost-Effectiveness Analysis, 1974–2018121
How Much Does It Cost to Research and Develop a New Drug? A Systematic Review and Assessment121
An Updated Systematic Review of Cost-Effectiveness Analyses of Drugs for Osteoporosis67
What are the Economic Costs to Society Attributable to Alcohol Use? A Systematic Review and Modelling Study57
The Growing Burden of Major Depressive Disorders (MDD): Implications for Researchers and Policy Makers53
Informing a Cost-Effectiveness Threshold for Health Technology Assessment in China: A Marginal Productivity Approach53
Common Problems, Common Data Model Solutions: Evidence Generation for Health Technology Assessment46
EQ-5D-Y Value Set for Slovenia45
Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations42
Estimating Transition Probabilities from Published Evidence: A Tutorial for Decision Modelers42
Estimating the Relationship Between EQ-5D-5L and EQ-5D-3L: Results from a UK Population Study35
Economic Evaluation of Digital Health Interventions: Methodological Issues and Recommendations for Practice34
Systematic Review of Conceptual, Age, Measurement and Valuation Considerations for Generic Multidimensional Childhood Patient-Reported Outcome Measures33
Economic Burden of Multiple Sclerosis in Low- and Middle‐Income Countries: A Systematic Review32
Valuation of SF-6Dv2 Health States in China Using Time Trade-off and Discrete-Choice Experiment with a Duration Dimension31
Global Economic Burden of Attention-Deficit/Hyperactivity Disorder: A Systematic Review30
Integrative Review of Managed Entry Agreements: Chances and Limitations29
The Use of a Discrete Choice Experiment Including Both Duration and Dead for the Development of an EQ-5D-5L Value Set for Australia29
Implementing Outcomes-Based Managed Entry Agreements for Rare Disease Treatments: Nusinersen and Tisagenlecleucel28
Guidance for the Harmonisation and Improvement of Economic Evaluations of Personalised Medicine26
Health State Utilities of Patients with Heart Failure: A Systematic Literature Review25
Recalibrating Health Technology Assessment Methods for Cell and Gene Therapies24
Productivity-Adjusted Life-Years: A New Metric for Quantifying Disease Burden24
0.25966906547546